Levosimendan for severe heart failure in hospital
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a medication called levosimendan to help people with severe heart failure who are still very short of breath even after standard treatment. The goal is to see if it can improve symptoms and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are currently in the hospital for worsening heart failure and still feel short of breath even at rest, despite getting IV water pills.
- Your heart's pumping strength (ejection fraction) is less than 40% (measured within the last year).
- You do not have severe kidney disease, are not on a breathing machine, and have not had major heart surgery or a device implanted in the last few months.
- You are not pregnant and have not had a stroke or serious bleeding recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving levosimendan early (a heart-strengthening medicine) improves outcomes compared with placebo, on top of standard inotropic support, in people with cardiogenic shock. It mainly looks at whether patients have fewer serious complications or deaths.
This study looks at how a heart medication called levosimendan works in the body of adults with severe cardiogenic shock. It aims to improve dosing for better outcomes.
This trial tests if the drug levosimendan can help people with a specific type of pulmonary hypertension (PH-HFpEF) feel less tired and breathless during daily activities, and improve their exercise ability.
This study tests if a heart medication called levosimendan helps people get off the breathing machine (ventilator) faster. It's for people who have been on a ventilator for more than 48 hours and have already tried and failed to breathe on their own.
This trial compares an LVAD device (a pump placed in the chest) plus medicines versus medicines alone for people with advanced, end-stage heart failure. It aims to see which approach works better to help patients live and stay out of the hospital.
This trial is studying a non-surgical (conservative) treatment approach for people being considered for a left ventricular assist device (LVAD). It may help some patients who are too sick or unable to tolerate standard heart failure medicines, but it will only match people with specific heart function and health-test results.
Hear when a new Acute Decompensated Heart Failure (ADHF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.